Company intelligence / Profile preview
Humanetics
- Ownership
- Private
- Development stage
- Commercial
Overview
Humanetics’ lead drug candidate BIO 300 (BYOGRAYZ™), a selective estrogen receptor beta agonist, has demonstrated positive Phase 2 results in improving pulmonary function in COVID patients and is Phase 2b-ready for NSCLC. It is also being positioned for Emergency Use Authorization as a medical countermeasure against acute radiation syndrome with strong support from the Department of Defense. Clinical data show efficacy in protecting normal tissues from radiation damage while potentially enhancing tumor response to radiotherapy.
- Therapeutic areas
- OtherHematologyPulmonologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Humanetics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Humanetics.